The U.S. Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib (BI 1810631) for the treatment of adult patients with ...

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer (NSCLC) as it has ...

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023Full year revenues increased 473% to $290.5 million versus ...

Laboratory Illustrative image Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib would be the first orally ...

The most common form of lung cancer is primarily found in non-smokers, a new study reveals. Doctors react to the surprising ...

The Global Cancer Immunotherapy Market achieved a valuation of $121.2 Billion in 2023 and is anticipated to exceed $245.37 ...

A Navy veteran recently said that an experimental immunotherapy treatment and his faith both played key roles in helping him defeat cancer.

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...